Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-28
2011-06-28
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07968569
ABSTRACT:
Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni et al.
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4810643 (1989-03-01), Souza
patent: 4999291 (1991-03-01), Souza
patent: 5059595 (1991-10-01), Le Grazie
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5134127 (1992-07-01), Stella et al.
patent: 5229496 (1993-07-01), Deeley et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5391485 (1995-02-01), Deeley et al.
patent: 5393870 (1995-02-01), Deeley et al.
patent: 5528823 (1996-06-01), Rudy, Jr. et al.
patent: 5580755 (1996-12-01), Souza
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5593990 (1997-01-01), D'Amato
patent: 5629327 (1997-05-01), D'Amato
patent: 5635517 (1997-06-01), Muller et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5698579 (1997-12-01), Muller
patent: 5712291 (1998-01-01), D'Amato
patent: 5731325 (1998-03-01), Andrulis, Jr. et al.
patent: 5733566 (1998-03-01), Lewis
patent: 5798368 (1998-08-01), Muller et al.
patent: 5874448 (1999-02-01), Muller et al.
patent: 5877200 (1999-03-01), Muller
patent: 5929117 (1999-07-01), Muller et al.
patent: 5955476 (1999-09-01), Muller et al.
patent: 6020358 (2000-02-01), Muller et al.
patent: 6071948 (2000-06-01), D'Amato
patent: 6077822 (2000-06-01), Dyrsting et al.
patent: 6114355 (2000-09-01), D'Amato
patent: 6140346 (2000-10-01), Andrulis, Jr. et al.
patent: 6228879 (2001-05-01), Green et al.
patent: 6235756 (2001-05-01), D'Amato
patent: 6281230 (2001-08-01), Muller et al.
patent: 6316471 (2001-11-01), Muller et al.
patent: 6326388 (2001-12-01), Man et al.
patent: 6335349 (2002-01-01), Muller et al.
patent: 6380239 (2002-04-01), Muller et al.
patent: 6395754 (2002-05-01), Muller et al.
patent: 6403613 (2002-06-01), Man et al.
patent: 6420414 (2002-07-01), D'Amato
patent: 6458810 (2002-10-01), Muller et al.
patent: 6469045 (2002-10-01), D'Amato
patent: 6476052 (2002-11-01), Muller et al.
patent: 6518298 (2003-02-01), Green et al.
patent: 6555554 (2003-04-01), Muller et al.
patent: 6673828 (2004-01-01), Green et al.
patent: 7119106 (2006-10-01), Muller et al.
patent: 7189740 (2007-03-01), Zeldis
patent: 7393862 (2008-07-01), Zeldis
patent: 7435745 (2008-10-01), D'Amato
patent: 2001/0018445 (2001-08-01), Huang et al.
patent: 2001/0022973 (2001-09-01), Ortyl et al.
patent: 2001/0056114 (2001-12-01), D'Amato
patent: 2002/0035090 (2002-03-01), Zeldis et al.
patent: 2002/0045643 (2002-04-01), Muller et al.
patent: 2002/0052398 (2002-05-01), D'Amato
patent: 2002/0054899 (2002-05-01), Zeldis
patent: 2002/0061923 (2002-05-01), D'Amato
patent: 2002/0128228 (2002-09-01), Hwu
patent: 2002/0161023 (2002-10-01), D'Amato
patent: 2002/0173658 (2002-11-01), Muller et al.
patent: 2002/0183360 (2002-12-01), Muller et al.
patent: 2003/0013739 (2003-01-01), Masferrer et al.
patent: 2003/0028028 (2003-02-01), Man et al.
patent: 2003/0045552 (2003-03-01), Robarge et al.
patent: 2003/0069428 (2003-04-01), Muller et al.
patent: 2003/0096841 (2003-05-01), Robarge et al.
patent: 2003/0139451 (2003-07-01), Shah et al.
patent: 2003/0144325 (2003-07-01), Muller et al.
patent: 2003/0181428 (2003-09-01), Green et al.
patent: 2003/0187024 (2003-10-01), D'Amato
patent: 2003/0191098 (2003-10-01), D'Amato
patent: 2003/0235909 (2003-12-01), Hariri et al.
patent: 2004/0029832 (2004-02-01), Zeldis
patent: 2004/0067953 (2004-04-01), Stein et al.
patent: 2004/0077685 (2004-04-01), Figg et al.
patent: 2004/0077686 (2004-04-01), Dannenberg et al.
patent: 2004/0087546 (2004-05-01), Zeldis
patent: 2004/0091455 (2004-05-01), Zeldis
patent: 2004/0122052 (2004-06-01), Muller et al.
patent: 2004/0147558 (2004-07-01), Treston et al.
patent: 2004/0266809 (2004-12-01), Emanuel et al.
patent: 2005/0049265 (2005-03-01), Adams
patent: WO 92/14455 (1992-09-01), None
patent: WO 94/20085 (1994-09-01), None
patent: WO 98/03502 (1998-01-01), None
patent: WO 98/54170 (1998-12-01), None
patent: WO 01/70275 (2001-09-01), None
patent: WO 01/87307 (2001-11-01), None
patent: WO 02/015926 (2002-02-01), None
patent: WO 02/059106 (2002-08-01), None
patent: WO 02/064083 (2002-08-01), None
patent: WO03086373 (2003-10-01), None
Corral et al. Immunomodulation by thalidomide and thalidomide analogues . . . Ann. Rheum. 1999; 58; 107-13.
Kyle et al. (“The Application of Thalidomide in Multiple Myeloma”, Semin Oncol. Dec. 2001; 28(6):583-7).
Davies et al. (“Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma”, Blood. Jul. 1, 2001;98(1):210-6).
Broder et al. (“Dideoxycytidine: current clinical experience and future prospects. A summary.”, Am J Med. May 21, 1990;88(5B):31S-33S).
Filella et al. (Cancer Detect Prey. 1996;20(1):52-6).
Raza et al., 2001, “Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplatic syndromes,” Blood 98(4):958-965.
Shah et al., 1999, “Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis,” J. Med. Chem. 42:3014-3017.
Shibata et al., 1995, “N-alkylphthalimides: structural requirement of thalidomidal action on 12-0-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor a production by human leukemia HL-60 cells,” Chem. Pharm. Bull. 43(1):177-179.
Shimazawa et al., 1999, “Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide,” Biol. Pharm. Bull. 22(2):224-226.
Rubin et al, “Principles of Cancer Treatment-l”, 12 ONCO IV I, May 2003.
Wilen et al., 1977, Tetrahedron 33:2725.
Wilen, 1972,Tables of Resolving Agents and Optical Resolutions, E.L. Eliel, ed., Univ. of Notre Dame Press, Notre Dame, IN pp. 268.
Wolff ed., 1995,Burger's Medicinal Chemistry and Drug Discovery, 5thed.., pp. 172-178, 949-982.
Bach, 1963, “Thalidomide in Cancer Chemotherapy,”The Lancet, No. 1271, p. 71.
Bach, 1963, “Studies on the Possible Anti-Neoplastic Effect of Thalidomide,”Acta Pathologica Et Microbiologica Scandinavica59:491-499.
Chaundhry, 1966,Cancer Research, “Effect of Prednisolone and Thalidomide on Induced Submandibular Gland Tumors in Hamster,” 26(part 1)1884-86.
DiPaolo, 1963, “Effect of Thalidomide on a Variety of Transplantable Tumors,”Cancer Chemotherapy ReportsNo. 29, p. 99-102.
DiPaolo, 1963, “In vitro Test Systems for Cancer Chemotherapy, II. Correlation of in vitro Inhibition of Dehydrogenase and Growth with in vivo Inhibition of Ehrlich Asoites Tumor,”Proceedings of the Society for Experimental Biology&Medicine, 114:384-387.
DiPaolo, 1964, “Thalidomide: Effects on Ehrlich Ascites Tumor Cells in vitro” Science 144:1583.
Mauad, 1963, “Clinical Improvements Obtained in Advanced Caner Patients with Treatment with Thalidomide Associated with Hormones,” AnaisPaulistas de Medicina e Cirurgia86:13-40.
Roe and Mitchley, 1963, “Thalidomide and Neoplasia”Nature200:1016-1017.
Alexanian et al., 2004, “VTD (Velcade, thalidomide, dexamethasone) as primary therapy for
Celgene Corporation
Jones Day
Krass Frederick
Simmons Chris E
LandOfFree
Methods for treatment of multiple myeloma using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of multiple myeloma using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of multiple myeloma using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2739191